Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases"

Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases"

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 224(2021) vom: 01. März, Seite 108665
1. Verfasser: Talotta, Rossella (VerfasserIn)
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Letter Comment Autoimmunity Autoinflammation COVID-19 Immune response SARS-CoV-2 Type I interferon mRNA vaccine COVID-19 Vaccines mehr... RNA 63231-63-0
LEADER 01000naa a22002652 4500
001 NLM319925196
003 DE-627
005 20231225172504.0
007 cr uuu---uuuuu
008 231225s2021 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2021.108665  |2 doi 
028 5 2 |a pubmed24n1066.xml 
035 |a (DE-627)NLM319925196 
035 |a (NLM)33429060 
035 |a (PII)S1521-6616(21)00002-4 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Talotta, Rossella  |e verfasserin  |4 aut 
245 1 0 |a Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases" 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 19.02.2021 
500 |a Date Revised 21.12.2022 
500 |a published: Print-Electronic 
500 |a CommentOn: Clin Immunol. 2020 Aug;217:108480. - PMID 32461193 
500 |a Citation Status MEDLINE 
650 4 |a Letter 
650 4 |a Comment 
650 4 |a Autoimmunity 
650 4 |a Autoinflammation 
650 4 |a COVID-19 
650 4 |a Immune response 
650 4 |a SARS-CoV-2 
650 4 |a Type I interferon 
650 4 |a mRNA vaccine 
650 7 |a COVID-19 Vaccines  |2 NLM 
650 7 |a RNA  |2 NLM 
650 7 |a 63231-63-0  |2 NLM 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 224(2021) vom: 01. März, Seite 108665  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:224  |g year:2021  |g day:01  |g month:03  |g pages:108665 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2021.108665  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 224  |j 2021  |b 01  |c 03  |h 108665